Catalyst

Slingshot members are tracking this event:

FDA reviews Esperion (ESPR) Phase 3 trial of bempedoic acid for low density lipoprotein cholesterol (LDL-C) and announces it is satisfactory to support approval

Source Link:
https://seekingalpha.com/pr/16775162-esperion-announces-fda-confirmation-regarding-regulatory-pathway-approval-ldl-c-lowering

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
ESPR Community voting in process
SIGN ME UP
I want to vote! LOG ME IN
Now!
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Occurred on:
Mar 20, 2017
Related Projects Image

  • Don’t see a project related to the catalyst you care about?

Related Keywords Fda, Bempedoic Acid, Low Density Lipoprotein Cholesterol, Phase 3
About Us
Media Center
Connect with Us
© 2024 Slingshot Insights. All rights reserved.